Down-regulation of tumor suppressor PDCD4 expression in endometrium of adenomyosis patients

Liu, Y.; Tan, Xiao Di; Wang, Zhaoguang; Li, Y.; Gao, Meng; Fang, Zhou; Sun, Yuchen; Zhang, L.; Wang, X.; Wei, Zengtao

doi:10.1016/j.retram.2016.04.008

Cited by 9 publications

(10 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of the 64‐kDa protein PDCD4 is dramatically downregulated in numerous cancers, including colorectal, lung, gastric, and breast cancers, and is therefore generally recognized as a vital tumor suppressor . To date, a set of miRNAs have been confirmed to target PDCD4 , such as miR‐96 in glioma cancer, miR‐4262 in hepatocellular carcinoma, and miR‐499 in oropharyngeal cancer .…”

Section: Introductionmentioning

confidence: 99%

“…[12][13][14][15] The expression of the 64-kDa protein PDCD4 is dramatically downregulated in numerous cancers, including colorectal, lung, gastric, and breast cancers, and is therefore generally recognized as a vital tumor suppressor. [16][17][18][19] To date, a set of miRNAs have been confirmed to target PDCD4, such as miR-96 in glioma cancer, miR-4262 in hepatocellular carcinoma, and miR-499 in oropharyngeal cancer. [20][21][22] Although miR-155 and PDCD4 have been shown to play distinct roles in NSCLC, the exact mechanism of miR-155/PDCD4 is not yet clear.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MiR‐155 inhibits proliferation and invasion by directly targeting PDCD4 in non‐small cell lung cancer

Feng

Song

et al. 2017

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundMicroRNAs are often abnormally expressed in human non‐small cell lung cancer (NSCLC) and are thought to play a critical role in the emergence or maintenance of NSCLC by binding to its target messenger RNA. We assessed the effects of miR‐155 on cell proliferation and invasion to elucidate the role played by miR‐155/PDCD 4 in NSCLC.MethodsQuantitative reverse transcription‐PCR, Western blotting, and cell counting kit‐8, luciferase, and transwell invasion assays were conducted on a normal human bronchial epithelial cell line (BEAS‐2B) and three NSCLC cell lines (SPC‐A‐1, A549, and H2170).ResultsWe confirmed that miR‐155 was upregulated, while PDCD 4 messenger RNA and protein levels were downregulated in NSCLC cell lines. miR‐155 negatively regulated PDCD 4 at both transcriptional and post‐transcriptional levels. Moreover, PDCD 4 was forecast as an assumed target of miR‐155 using bioinformatic methods and we demonstrated that PDCD 4 was a direct target of miR‐155 using luciferase reporter assays. Furthermore, PDCD 4 overexpression could restrain NSCLC proliferation and invasion induced by miR‐155.ConclusionOur results collectively demonstrate that miR‐155 exerts an oncogenic role in NSCLC by directly targeting PDCD 4.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

MiR‐155 inhibits proliferation and invasion by directly targeting PDCD4 in non‐small cell lung cancer

Feng

Song

et al. 2017

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…xii) PDCD4. PDCD4 is involved in the apoptotic pathway and is a tumor suppressor gene, which is downregulated in adenomyosis (60) and endometriosis (61) possibly through the nuclear factor (NF)-κB/mammalian target of rapamycin (MMP)2/MMP9 signaling pathway.…”

Section: Functional Pathways Of Adenomyosis Candidate Genesmentioning

confidence: 99%

Bioinformatics strategy for the screening of key genes to differentiate adenomyosis from endometriosis (Review)

2019

View full text Add to dashboard Cite

“…[3][4][5][6][7] The treatment options for adenomyosis are summarized by Soave et al 8 and mainly include medical treatment, high intensity focused ultrasound (HIFU), surgery and combination therapy. [3][4][5][6][7] The treatment options for adenomyosis are summarized by Soave et al 8 and mainly include medical treatment, high intensity focused ultrasound (HIFU), surgery and combination therapy.…”

mentioning

confidence: 99%

“…women's quality of life and leads to a heavy burden on the cost of health care. [3][4][5][6][7] The treatment options for adenomyosis are summarized by Soave et al 8 and mainly include medical treatment, high intensity focused ultrasound (HIFU), surgery and combination therapy. 8 Since hysterectomy is not accepted by most patients, drug therapy is still the firstline treatment for adenomyosis.…”

mentioning

confidence: 99%

A new trick for an old dog: The application of mifepristone in the treatment of adenomyosis

Che

Wang

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Adenomyosis is also called internal endometriosis and affects about 20% of reproductive‐aged women. It seriously reduces life quality of patients because current drug therapies face with numerous challenges. Long‐term clinical application of mifepristone exhibits wonderful therapeutic effects with mild side‐effects in many disorders since 1982. Since adenomyosis is a refractory disease, we investigate whether mifepristone can be applied in the treatment of adenomyosis. In this study, we investigated the direct effects of mifepristone on human primary eutopic endometrial epithelial cells and stromal cells in adenomyosis. We found that mifepristone causes cell cycle arrest through inhibiting CDK1 and CDK2 expressions and induces cell apoptosis via the mitochondria‐dependent signalling pathway in endometrial epithelial cells and stromal cells of adenomyosis. Furthermore, mifepristone inhibits the migration of endometrial epithelial cells and stromal cells through decreasing CXCR4 expression and restricts the invasion of endometrial epithelial cells via suppression of epithelial‐mesenchymal transition in adenomyosis. We also found that mifepristone treatment decreases the uterine volume, CA125 concentration and increases the haemoglobin concentration in serum for adenomyosis patients. Therefore, we demonstrate that mifepristone could serve as a novel therapeutic drug in the treatment of adenomyosis, and therefore, the old dog can do a new trick.

show abstract

Down-regulation of tumor suppressor PDCD4 expression in endometrium of adenomyosis patients

Cited by 9 publications

References 28 publications

MiR‐155 inhibits proliferation and invasion by directly targeting PDCD4 in non‐small cell lung cancer

MiR‐155 inhibits proliferation and invasion by directly targeting PDCD4 in non‐small cell lung cancer

Bioinformatics strategy for the screening of key genes to differentiate adenomyosis from endometriosis (Review)

A new trick for an old dog: The application of mifepristone in the treatment of adenomyosis

Contact Info

Product

Resources

About